Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last SFr.3.18 CHF
Change Today -0.10 / -3.05%
Volume 153.1K
ADXN On Other Exchanges
Symbol
Exchange
ADXN is not on other exchanges.
As of 11:43 AM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

addex pharmaceuticals ltd (ADXN) Snapshot

Open
SFr.3.26
Previous Close
SFr.3.28
Day High
SFr.3.26
Day Low
SFr.3.12
52 Week High
07/4/14 - SFr.5.24
52 Week Low
06/3/14 - SFr.2.02
Market Cap
37.2M
Average Volume 10 Days
70.9K
EPS TTM
SFr.-0.18
Shares Outstanding
11.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ADDEX PHARMACEUTICALS LTD (ADXN)

Related News

No related news articles were found.

addex pharmaceuticals ltd (ADXN) Related Businessweek News

No Related Businessweek News Found

addex pharmaceuticals ltd (ADXN) Details

Addex Therapeutics Ltd, together with its subsidiaries, discovers, develops, and commercializes small-molecule pharmaceutical products for the treatment of human health. Its lead programs include Dipraglurant ADX48621 for the treatment of Parkinson’s disease levodopa-induced dyskinesia and dystonia; ADX71149 for an undisclosed CNS disorders; ADX71441 for the treatment of Charcot-Marie-Tooth type 1A neuropathy; and ADX71441 for the treatments of addiction. The company focuses on the discovery of oral allosteric modulators of G-protein coupled receptors. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. to develop mGluR2PAM compounds for the treatment of human health; and collaboration with Dystonia Medical Research Foundation to prepare a phase IIa proof of concept clinical study in a form of dystonia. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

5 Employees
Last Reported Date: 04/30/15
Founded in 2002

addex pharmaceuticals ltd (ADXN) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: SFr.384.0K
Compensation as of Fiscal Year 2014.

addex pharmaceuticals ltd (ADXN) Key Developments

Addex Therapeutics Announces Earnings Results for the Year 2014

Addex Therapeutics announced earnings results for the year 2014. For the year, the company reported its net loss in 2014 shrunk to CHF 1.8 million from CHF 14.5 million a year earlier, due to a decrease in the cash burn to CHF 900,000 from CHF 12.3 million in 2013. Full-year net income climbed to CHF 700,000 from CHF 100,000 in 2013.

Addex Therapeutics Announces Earnings Results for the Second Half and Full Year of 2014

Addex Therapeutics announced earnings results for the second half and full year of 2014. For the year, the company reported income of CHF 0.7 million against CHF 0.1 million a year ago. Total operating loss was CHF 1.8 million against CHF 14.5 million a year ago. Net loss for the period was CHF 1.8 million against CHF 14.5 million a year ago. Basic and diluted net loss per share was CHF 0.18 against CHF 1.60 a year ago. Net cash used (cash burn) was CHF 0.9 million against CHF 12.3 million a year ago. For the second half of 2014, the company reported income of CHF 0.7 million. Total operating loss was CHF 0.8 million against CHF 0.5 million a year ago. Net loss for the period was CHF 0.8 million against CHF 0.5 million a year ago. Basic and diluted net loss per share was CHF 0.18 against CHF 0.06 a year ago.

Addex Therapeutics Ltd. Presents at CF&B European Small Cap Event, Apr-27-2015

Addex Therapeutics Ltd. Presents at CF&B European Small Cap Event, Apr-27-2015 . Venue: Paris, France.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ADXN:SW SFr.3.18 CHF -0.10

ADXN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ADXN.
View Industry Companies
 

Industry Analysis

ADXN

Industry Average

Valuation ADXN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 14.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADDEX PHARMACEUTICALS LTD, please visit www.addextherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.